Genomes and Genes
prostate specific antigen
Gene Symbol: prostate specific antigen
Description: kallikrein related peptidase 3
Alias: APS, KLK2A1, PSA, hK3, prostate-specific antigen, P-30 antigen, gamma-seminoprotein, kallikrein-3, semenogelase, seminin
Publications600 found, 100 shown here
- Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasmaP Cohen
Department of Pediatrics, Stanford University Medical Center, California 94305
J Clin Endocrinol Metab 75:1046-53. 1992..Prostate-specific antigen (PSA) is a serine protease found in semen...
- Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitorsA Christensson
Department of Clinical Chemistry, University of Lund, Malmo General Hospital, Sweden
Eur J Biochem 194:755-63. 1990Prostate-specific antigen (PSA) is one of the three most abundant prostatic-secreted proteins in human semen...
- Human prostate-specific antigen: structural and functional similarity with serine proteasesK W Watt
Proc Natl Acad Sci U S A 83:3166-70. 1986....
- A structural model for the prostate disease marker, human prostate-specific antigenB O Villoutreix
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037
Protein Sci 3:2033-44. 1994Prostate-specific antigen (PSA) provides an excellent serum marker for prostate cancer, the most frequent form of cancer in American males. PSA is a 237-residue protease based on sequence homology to kallikrein-like enzymes...
- Substrate specificity of prostate-specific antigen (PSA)G S Coombs
Corvas International, Department of Molecular Biology, San Diego, CA 92121, USA
Chem Biol 5:475-88. 1998The serine protease prostate-specific antigen (PSA) is a useful clinical marker for prostatic malignancy...
- Generation of angiostatin-like fragments from plasminogen by prostate-specific antigenH H Heidtmann
St Joseph Hospital, Bremerhaven, Germany
Br J Cancer 81:1269-73. 1999..It is generated from plasminogen by limited proteolysis. We show that prostate-specific antigen (PSA), a serine proteinase secreted by human prostate and human prostate cancer cells, is able to convert Lys-..
- Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitorJ Malm
Section for Clinical Chemistry, Department of Laboratory Medicine, Lund University, University Hospital Malmo, Malmo, Sweden
Prostate 45:132-9. 2000In semen, prostate-specific antigen (PSA or hK3) digests the gel proteins semenogelin I and II, resulting in liquefaction and the release of motile spermatozoa...
- Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 regionL Gan
Chiroscience R and D Inc 1631 220th St SE Bothell, WA 98021, USA
Gene 257:119-30. 2000..The proteases, excluding the kallikrein genes, share approximately 40% of their sequences suggesting that the serine protease gene cluster on chromosome 19q13 arose from ancient gene duplications...
- Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft modelsS R Denmeade
The Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Baltimore, Maryland 21231, USA
Prostate 48:1-6. 2001Prostate-specific antigen (PSA) targeted prodrugs are under development in our laboratory...
- Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cellsRui Medeiros
Molecular Oncology Unit, Instituto Portugues de Oncologia, Porto, Portugal
Prostate 53:88-94. 2002The prostate specific antigen (PSA) gene has a polymorphic androgen response element (ARE) sequence with two alleles, A and G. PSA A-allele carriers have higher serum PSA levels in healthy men (HM).
- Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer riskAndrea Gsur
Division of Applied and Experimental Oncology, Institute of Cancer Research, University of Vienna, Austria
Carcinogenesis 23:1647-51. 2002..by binding to androgen-response elements (AREs) in target genes, such as the prostate-specific antigen (PSA). In the ARE-I sequence of the PSA gene an adenine to guanine polymorphism is described...
- Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasionKenichiro Ishii
Laboratory of Pharmaceutics, Gifu Pharmaceutical University, 5 6 1 Mitahora Higashi, Gifu 502 8585, Japan
Cancer Lett 207:79-87. 2004Prostate-specific antigen (PSA), which is used as a marker for the diagnosis and monitoring of prostate cancer, is a kallikrein protease which could potentially play a role in human prostate cancer cell invasion...
- Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigenS L Dallas
Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
J Cell Physiol 202:361-70. 2005..We investigated whether prostate specific antigen (PSA), a serine protease used as a clinical marker for prostate cancer, could play a role in the ..
- Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3Piotr Laidler
Institute of Medical Biochemistry, Jagiellonian University, Medical College, ul Kopernika 7, 31 034 Krakow, Poland
Arch Biochem Biophys 435:1-14. 2005..The values of interaction force between the same anti-PSMA antibodies and all studied cells were almost identical (45-64pN), indicating antigenic similarity of the membrane form of PSMA expressed in LNCaP, PC-3, and Du 145 cells...
- Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressivenessMine S Cicek
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Lerner School of Medicine, Ohio, USA
Cancer Epidemiol Biomarkers Prev 14:2173-7. 2005..androgen metabolism: CYP1B1 (two single nucleotide polymorphisms: 355G/T and 4326C/G), prostate-specific antigen (PSA/KLK3 (three single nucleotide polymorphisms: -158A/G, -4643G/A, and -5412C/T), and CYP11alpha [(tttta)(n) repeat], ..
- Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African-American menJ L Beebe-Dimmer
Department of Urology, University of Michigan Medical School, Ann Arbor MI, USA
Prostate Cancer Prostatic Dis 9:50-5. 2006A major problem with the use of serum prostate-specific antigen (PSA) in predicting prostate cancer risk is the considerable variability of such measurements. Cramer et al...
- Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSAGianluca Severi
Cancer Epidemiology Center, The Cancer Council Victoria, Melbourne, Victoria, Australia
Cancer Epidemiol Biomarkers Prev 15:1142-7. 2006An A to G substitution, rs925013, in the promoter of the prostate-specific antigen gene (PSA) was recently found to be associated with promoter activity and circulating PSA levels...
- Multiple newly identified loci associated with prostate cancer susceptibilityRosalind A Eeles
The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
Nat Genet 40:316-21. 2008..or with a family history of disease, and 1,894 population-screened controls with a low prostate-specific antigen (PSA) concentration (<0.5 ng/ml). We analyzed these samples for 541,129 SNPs using the Illumina Infinium platform...
- PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsyRodrigo Mattos dos Santos
Institute of Biosciences, Sao Paulo State University, UNESP, Botucatu, Sao Paulo, Brazil
DNA Cell Biol 27:497-503. 2008The aim of the present study was to examine the impact of polymorphisms in prostate-specific antigen (PSA) and androgen-related genes (AR, CYP17, and CYP19) on prostate cancer (PCa) risk in selected high-risk patients who underwent ..
- Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levelsC Jesser
Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
Br J Cancer 99:1743-7. 2008Prostate-specific antigen (PSA) is a protease produced in the prostate that cleaves insulin-like growth factor binding protein-3 and other proteins...
- Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohortAndrew J Vickers
Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, 307 E 63rd St, New York, NY 10021, USA
Eur Urol 56:753-60. 2009It has been suggested that changes in prostate-specific antigen (PSA) over time (ie, PSA velocity [PSAV]) aid prostate cancer detection. Some guidelines do incorporate PSAV cut points as an indication for biopsy.
- A comprehensive resequence analysis of the KLK15-KLK3-KLK2 locus on chromosome 19q13.33Hemang Parikh
Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Gaithersburg, MD 20877, USA
Hum Genet 127:91-9. 2010..33 are associated with serum prostate-specific antigen (PSA) levels...
- Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cellsAstrid K Whitbread
Institute of Health and Biomedical Innovation and School of Life Sciences, Queensland University of Technology, Australia
Biol Chem 391:461-6. 2010b>PSA-RP2 is a variant transcript expressed from the PSA gene that is conserved in gorillas, chimpanzees and humans suggesting a particular relevance for this transcript in these primates...
- Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologiesAwatef Ben Jemaa
Unit of Immunology and Microbiology Environmental and Carcinogenesis, Faculty of Sciences of Bizerte, 7021 Zarzouna, University of 7 November at Carthage, Tunisia
J Exp Clin Cancer Res 29:171. 2010The present study was undertaken to relate the co-expression of prostate-associated antigens, PSMA and PSA, with the degree of vascularization in normal and pathologic (hyperplasia and cancer) prostate tissues to elucidate their possible ..
- Association of G/A polymorphism, rs266882, in AREI region of the prostate-specific antigen gene with prostate cancer risk and clinicopathological featuresMohammad Samzadeh
Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Urol J 9:691-9. 2012To determine the association of prostate-specific antigen (PSA) 158A/G polymorphism with clinicopathologic characteristics of the disease and prostate cancer (PCa) risk.
- Growth regulation of prostatic stromal cells by prostate-specific antigenD M Sutkowski
Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
J Natl Cancer Inst 91:1663-9. 1999Prostate-specific antigen (PSA) is a serine protease that can cleave insulin-like growth factor-binding protein-3 (IGFBP3), thereby decreasing its affinity for insulin-like growth factor-I (IGF-I)...
- Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levelsScott D Cramer
Department of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
J Natl Cancer Inst 95:1044-53. 2003Recent evidence suggests that genetic variation in the promoter of the prostate-specific antigen (PSA) gene may contribute to individual variation in serum PSA levels...
- Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese populationLi Zhong Wang
Department of Urology, Akita University School of Medicine, 1 1 1 Hondo, Akita 010 8543, Japan
Cancer Lett 202:53-9. 2003Recent studies have indicated that the prostate-specific antigen (PSA) gene polymorphisms may be associated with the risk of prostate cancer in Caucasian populations...
- The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancerChih Hung Chiang
Department of Surgery, Taipei Veterans General Hospital, School of Medicine, National Yang Ming University, Taipei, Taiwan, Republic of China
J Urol 171:1529-32. 2004..guanine (G) substitution is identified at position -158 in the androgen response elements region of the prostate specific antigen (PSA) gene...
- Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancerMargaret C Binnie
Prostate Research Group, Division of Oncology, School of Molecular and Clinical Medicine, Western General Hospital, Edinburgh, United Kingdom
Prostate 63:309-15. 2005Recent data has suggested that polymorphisms in the prostate specific antigen (PSA) may increase prostate cancer (PC) risk. The PSA gene contains a G/A substitution in the androgen response element (ARE) 1 region...
- Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancerGeorg Schatzl
Department of Urology, Medical University of Vienna, Vienna, Austria
Urology 65:1141-5. 2005To examine the impact of polymorphism in the androgen-responsive element I region of the prostate-specific antigen (PSA) gene on the serum testosterone level and Gleason score in patients with newly diagnosed, untreated prostate cancer (..
- Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cellsT L Veveris-Lowe
School of Life Sciences and Science Research Centre, Queensland University of Technology, Brisbane, Australia
Endocr Relat Cancer 12:631-43. 2005Prostate-specific antigen (PSA) and the related kallikrein family of serine proteases are current or emerging biomarkers for prostate cancer detection and progression...
- Genetic Susceptibility to Prostate Cancer: Prostate-specific Antigen and its Interaction with the Androgen Receptor (United States)Weiva Sieh
Division of Medical Genetics, Department of Medicine, University of Washington, Box 357720, Seattle, WA, 98195 7720, USA
Cancer Causes Control 17:187-97. 2006To determine whether directly observed prostate-specific antigen (PSA) promoter diploid haplotype, either alone or in conjunction with androgen receptor (AR) genotype, is associated with prostate cancer risk.
- Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European originProdipto Pal
Department of Environmental Health, Center for Genome Information, University of Cincinnati Medical Center, OH 45267 0056, USA
Hum Genet 122:251-9. 2007..Four of the studied SNPs show positive associations with serum PSA levels...
- Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancerGeorgios Pampalakis
Department of Pharmacy, University of Patras, Rion Patras 26500, Greece
Clin Biochem 41:591-7. 2008We aimed to identify novel splice variants of prostate-specific antigen/or human kallikrein 3 (PSA/KLK3), the most widely used serum biomarker for case-finding, screening and monitoring of prostate cancer.
- An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell linesMiltiadis Paliouras
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto M5G 1L5, ON, Canada
Biol Chem 389:773-80. 2008..itself in several forms, including a percentage of cancers that show reduced levels of prostate-specific antigen (PSA) and can progress without the need for the ligand or active receptor...
- Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancerScott D Cramer
Department of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
Cancer Epidemiol Biomarkers Prev 17:2451-7. 2008The serum test for the secreted protease prostate-specific antigen (PSA) is the most widely used screening tool for prostate cancer...
- Association of prostate cancer risk variants with clinicopathologic characteristics of the diseaseJianfeng Xu
Center for Cancer Genomics, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
Clin Cancer Res 14:5819-24. 2008..Fifteen independent genetic variants have been implicated in prostate cancer risk by recent genome-wide association studies. However, their association with clinicopathologic features of prostate cancer is uncertain...
- Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patientsA Karim Kader
Center for Cancer Genomics, Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
Prostate 69:1195-205. 2009..Their association with PCa aggressiveness and clinicopathologic variables is inconclusive...
- Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancerRobert J Klein
Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer Prev Res (Phila) 3:611-9. 2010..of the prostate: KLK2 (encoding kallikrein-related peptidase 2; hK2), KLK3 (encoding prostate-specific antigen; PSA), and MSMB (encoding beta-microseminoprotein)...
- PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibilityJohn Lai
Cluster for Molecular Biotechnology, School of Life Sciences and Science Research Centre, Queensland University of Technology, Victoria Park Road, Kelvin Grove, Brisbane, QLD 4059, Australia
Carcinogenesis 28:1032-9. 2007The proximal promoter of the kallikrein-related peptidase 3 gene (KLK3/PSA) contains a single-nucleotide polymorphism (G-158A) located within the second canonical half-site for the prostate-specific antigen (PSA) androgen response ..
- Biochemical characteristics and recent biological knowledge on prostate-specific antigenE Seregni
Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
Tumori 82:72-7. 1996..in 1971, much new information has been obtained about the biology and expression of prostate-specific antigen (PSA)...
- Racial differences in the androgen/androgen receptor pathway in prostate cancerC A Pettaway
Department of Urology, University of Texas MD Anderson Cancer Center, Houston 77030, USA
J Natl Med Assoc 91:653-60. 1999..Collectively, these data strongly suggest racial differences within the androgen/androgen receptor pathway not only exist but could be one cause of clinically observed differences in the biology of prostate cancer among racial groups...
- Is acid phosphatase (PAP) still justified in the management of prostatic cancer?M Kontturi
Department of Surgery, Oulu University Central Hospital, Finland
Acta Oncol 30:169-70. 1991The usefulness of acid phosphatase (PAP) and prostate specific antigen (PSA) is compared...
- Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic featuresW Demark-Wahnefried
Division of Urologic Surgery, Duke University Medical Center, Durham, North Carolina, USA
Urology 58:47-52. 2001..58); however, among men with Gleason sums of 6 or less (n = 19), the PSA values were 7.1 +/- 3.9 ng/mL and 6.4 +/- 4.1 ng/mL (P = 0.10). The mean proliferation index was 7.4 +/- 7...
- Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transferJ W Simons
Johns Hopkins Oncology Center, Brady Urological Institute, and Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
Cancer Res 59:5160-8. 1999..No antibodies against prostate-specific antigen were detected. These data suggest that both T-cell and B-cell immune responses to human PCA can be generated by treatment with irradiated, GM-CSF gene-transduced PCA vaccines...
- Prostate-specific antigen and androgens in African-American and white normal subjects and prostate cancer patientsS O Asbell
Albert Einstein Medical Center, Department of Radiation Oncology, Philadelphia, Pennsylvania, USA
J Natl Med Assoc 92:445-9. 2000..Blood from 38 screened men (mean age 65) with prostate-specific antigen (PSA) less than 4 ng/mL and normal rectal examination seen at the AEMC Cancer Center was studied using standard ..
- Diagnosis and treatment of benign prostatic hyperplasia. Practice patterns of primary care physiciansM M Collins
General Medicine Division, Massachusetts General Hospital, Boston 02114, USA
J Gen Intern Med 12:224-9. 1997..Some of their diagnostic evaluations vary from the recommendations of a national guideline and urologists' practices. Referral thresholds appear to vary considerably...
- Alpha 2-macroglobulin-mediated degradation of amyloid beta 1--42: a mechanism to enhance amyloid beta catabolismD Lauer
Institute of Biochemistry, University of Leipzig, Liebigstrasse 16, 04103 Leipzig, Germany
Exp Neurol 167:385-92. 2001..These results suggest that up-regulation of A beta catabolism could probably reduce the risk of developing AD by preventing A beta accumulation in brain and vasculature...
- Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancerS Vijayakumar
Department of Radiation Oncology, Michael Reese Hospital, Center for Radiation Therapy, University of Chicago, Illinois, USA
J Natl Med Assoc 87:813-9. 1995..free testosterone, androstenedione, luteinizing hormone, or prolactin) have any influence on serum prostate specific antigen (PSA) levels in patients with stage A-C prostate cancer...
- Prostate specific antigen. A reviewM K Brawer
Department of Urology, University of Washington, Seattle
Acta Oncol 30:161-8. 1991Despite its identification in the 1970s, prostate specific antigen (PSA) has only recently gained widespread utility...
- The role of free to total prostate-specific antigen ratio for prostate cancer in screening patients with total serum levels between 4 and 20 ng/mlC T Wu
Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, Taipei
Chang Gung Med J 23:142-8. 2000BACKGROUND: We retrospectively tried to determine if the free to total prostate-specific antigen (f/t PSA) ratio could improve the specificity of PSA in prostate cancer screening of patients with total serum levels between 4 and 20 ng/ml...
- Prostate-specific antigen testing practices and outcomesR M Hoffman
Department of Medicine, Albuquerque Veterans Affairs Medical Center, University of New Mexico, 87108, USA
J Gen Intern Med 13:106-10. 1998OBJECTIVES: To characterize prostate-specific antigen (PSA) testing practices in a hospital-based primary care clinic, and to determine the outcomes of PSA testing, including urology referrals, biopsies, cancers detected, and cancer ..
- Prostate cancer screening practices and beliefsJ D Voss
Division of General Medicine, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908, USA
J Gen Intern Med 16:831-7. 2001OBJECTIVE: To examine primary care physician prostate-specific antigen (PSA) testing and prostate cancer screening beliefs, practices, and trends over time. DESIGN: Longitudinal physician survey...
- The importance of patient preference in the decision to screen for prostate cancer. Prostate Patient Outcomes Research TeamA B Flood
Department of Community and Family Medicine, Dartmouth Medical School, Hanover, NH 03755-3863, USA
J Gen Intern Med 11:342-9. 1996..This study examines how information about prostate-specific antigen (PSA) testing and the uncertain benefits of treating prostate cancer affects patients' desire for PSA testing...
- Correlation of digital rectal examination, prostate specific antigen, and transrectal ultrasound in prostate carcinoma in African AmericansR I Sibley
Sibley Medical Associates, Hampton, Virginia, USA
J Natl Med Assoc 89:318-23. 1997..include the two most cost-effective methods of early detection, digital rectal examination and prostate specific antigen. The use of transrectal ultrasound and guided biopsy improves the yield...
- The IGF axis in the prostateP Cohen
Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia
Horm Metab Res 26:81-4. 1994..PC-E are exquisitely sensitive to the mitogenic effects of IGFs. Finally, prostate specific antigen (PSA), secreted from PC- and found in seminal plasma, can function as a potent IGFBP-3 protease...
- Comparing two modalities of screening for prostate cancer: digital rectal examination + transrectal ultrasonography vs. prostate-specific antigenS Ciatto
Centro per lo Studio e la Prevenzione Oncologica, Florence, Italy
Tumori 81:225-9. 1995..examination (DRE) and transrectal ultrasonography (TRUS), or by serum prostate-specific antigen determination (PSA: cutoff 4 ng/ml)...
- Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurementsW J Shih
University of Kentucky Medical Center, Lexington
J Natl Med Assoc 84:1049-50. 1992..between Gleason scores of histopathology of prostate carcinoma and concurrent serum prostate-specific antigen (PSA) and prostate acid phosphatase (PAP) values, 65 men with prostate carcinoma were studied...
- Serum tumour markers in human prostatic carcinoma. The value of a marker panel for prognostic informationP Ekman
Department of Urology, Karolinska Hospital, Stockholm, Sweden
Acta Oncol 30:173-5. 1991Serum from 102 patients was analysed with regard to its content of prostatic acid phosphatase (PAP), prostate specific antigen (PSA), neopterin, osteocalcin, thymidine kinase, C-reactive protein, and of tissue polypeptide antigen (TPA)...
- Involvement of the C-terminal end of the prostrate-specific antigen in a conformational epitope: characterization by proteolytic degradation of monoclonal antibody-bound antigen and mass spectrometryS Michel
, , Marcy l'Etoile, France
J Mol Recognit 14:406-13. 2001Prostate-specific antigen (PSA), a 237-amino acid glycoprotein, encoded by the hKLK3 gene, is widely used as a serum marker for the diagnosis and management of prostate cancer...
- Changes in radical prostatectomy and radiation therapy rates for African Americans and whitesM Shaw
Division of Cellular Biology, Hektoen Institute for Medical Research, Chicago, IL 60612, USA
J Natl Med Assoc 92:281-4. 2000..changes in diagnosis rates of localized prostate cancer between the years before prostate-specific antigen (PSA) use (1973-1988) and the years after PSA use (1989-1996), to evaluate differences in RP and RT rates between the ..
- Roach's mathematical equations in predicting pathological stage in men with clinically localized prostate cancerM Medica
Luciano Giuliani Department of Urology, San Martino Hospital, University of Genoa, Italy
Tumori 87:130-3. 2001..Patients were divided into 25 groups, depending on preoperative PSA and the biopsy Gleason score...
- Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastasesD Fontana
Dipartimento di Scienze Cliniche e Biologiche, , Italy
Tumori 84:39-44. 1998..In conclusion, the results, although inconclusive, fail to support a clear advantage in terms of cost/benefit of chemotherapy plus hormone therapy over hormone treatment alone in advanced prostate cancer with bone involvement...
- Digital rectal examination versus transrectal ultrasound in detection of prostate cancer. Preliminary results from a study of a randomly selected populationU Norming
Department of Urology, , Stockholm, Sweden
Acta Oncol 30:277-9. 1991..compared the diagnostic value of digital rectal examination (DRE), transrectal ultrasound (TRUS) and prostate specific antigen (PSA). Altogether 62 prostate cancers were detected, corresponding to a detection rate of 3...
- Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patientsD Minardi
Institute of Urology, University of Ancona Medical School, Ancona, Italy
Urol Int 67:272-82. 2001The aim of our study was to evaluate the clinical usefulness of percent free prostate-specific antigen (PSA) [ratio of free PSA (fPSA) to total PSA (tPSA); f/tPSA] in prostatic pathology and its usefulness in monitoring prostatic cancer ..
- Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluidsJ Lovgren
Department of Laboratory Medicine, Lund University, University Hospital, Malmo, Sweden
J Androl 20:348-55. 1999It has been demonstrated that prostate-specific antigen (PSA), in spite of its name, can be detected in body fluids and tumors from a variety of organs...
- R75251 in prostate cancer patients in progression after first-line hormonal treatmentF Boccardo
Department of Medical Oncology II, National Institute for Cancer Research, Genoa, Italy
Tumori 80:276-9. 1994..In addition, 2 of them showed a more than 50% decrease of prostate-specific antigens (PSA). Overall, 50% of patients showed some decrease in PSA baseline levels. Overall tolerance to treatment was good...
- Percent of free serum prostate-specific antigen and histological findings in patients undergoing open prostatectomy for benign prostatic hyperplasiaV Scattoni
Department of Urology, Scientific Institute H San Raffaele, Milan, Italy
Eur Urol 36:621-30. 1999..of the surgical specimen in men undergoing open prostatectomy for benign prostatic hyperplasia (BPH) correlate with preoperative and postoperative total, free prostate-specific antigen (PSA) levels and the free-to-total PSA ratio.
- Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancerP S Bunting
Department of Laboratory Medicine, Sunnybrook and Women s College Health Sciences Centre, Ont
CMAJ 160:70-5. 1999The use of the prostate-specific antigen (PSA) test has been increasing rapidly in Canada since its introduction in 1988. The reasons for using the PSA test in patients without known prostate cancer are unclear...
- Prostate specific antigen density correlates with features of prostate cancer aggressivenessShilajit D Kundu
Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
J Urol 177:505-9. 2007An increased prostate specific antigen density (serum prostate specific antigen divided by prostate volume) is an established parameter to help determine the need to perform prostate biopsies...
- Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomyAhmed Magheli
Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
J Urol 179:1780-4; discussion 1784. 2008The usefulness of prostate specific antigen density for predicting pathological stage and biochemical recurrence after radical prostatectomy has not been well defined...
- Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of agingStacy Loeb
The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions and National Institute on Aging, National Institutes of Health Clinical Research Branch, Baltimore, Maryland, USA
J Urol 180:1314-7; discussion 1317. 2008Although prostate specific antigen velocity was proposed to increase the specificity of prostate specific antigen-based screening, there are little published data on the effect of differential prostate growth on prostate specific antigen ..
- Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experienceAhmed Magheli
Department of Urology, Charité Hospital Berlin, Campus Mitte, University Medicine Berlin, Berlin, Germany
J Urol 183:126-31. 2010We investigated the value of pretreatment prostate specific antigen density to predict Gleason score upgrading in light of significant changes in grading routine in the last 2 decades.
- Enhanced expression of prostate-specific antigen in the transition zone of the prostate. A characterization following prostatectomy for benign hyperplasiaF Recker
Urological Clinic, Kantonsspital Aarau, Switzerland
Eur Urol 33:549-55. 1998To determine whether the serum levels of total prostate-specific antigen (t-PSA), free PSA (f-PSA) and PSA complexed to alpha 1-antichymotrypsin (PSA-ACT) result from different expressions in various prostatic zones.
- Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSACuneyt Ozden
Second Urology Clinic of Ankara Numune Education and Research Hospital, Ankara, Turkey
Urol Int 71:150-3. 2003To evaluate early postoperative results of patients with elevated prostate-specific antigen (PSA) levels who underwent surgery due to benign prostatic hyperplasia (BPH).
- Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screeningJudd W Moul
Division of Urology and Duke Prostate Center, Duke University Medical Center, Durham, North Carolina 27710, USA
J Urol 177:499-503; discussion 503-4. 2007We identified age adjusted prostate specific antigen and prostate specific antigen velocity cut points for prostate cancer biopsy.
- The association between total prostate specific antigen concentration and prostate specific antigen velocityXiaoYing Yu
Department of Urology, Northwestern Feinberg School of Medicine, Chicago, Illinois 60611, USA
J Urol 177:1298-302; discussion 1301-2. 2007It has been previously demonstrated that a prostate specific antigen velocity greater than 2 ng/ml per year is associated with reduced cancer specific survival following radical prostatectomy or external beam radiation...
- Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to 10.0 ng/mlJ James Bruno
Department of Surgery, Division of Urology, Lenox Hill Hospital, New York, New York 10021, USA
J Urol 177:1741-4. 2007Percent free prostate specific antigen and prostate specific antigen density have been independently shown to increase the specificity of prostate cancer screening in men with prostate specific antigen levels between 4.1 and 10.0 ng/ml...
- Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/mlStacy Loeb
Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
J Urol 178:2348-52; discussion 2352-3. 2007A prostate specific antigen velocity threshold of 0.75 ng/ml per year has commonly been used to distinguish men with prostate cancer from those with benign prostate conditions...
- Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancerYong Hyun Park
Department of Urology, Seoul National University Hospital, Seoul, Korea
J Urol 181:2520-4; discussion 2525. 2009We determined the clinical significance of prostate specific antigen half-time and prostate specific antigen doubling time after the prostate specific antigen nadir as predictors of the response to androgen deprivation therapy for ..
- [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening studyBrian V Le
Department of Urology, Northwestern University, Chicago, Illinois 60611, USA
J Urol 183:1355-9. 2010Due to the limited specificity of prostate specific antigen for prostate cancer screening, there is an ongoing search for adjunctive biomarkers...
- Usefulness of prostate-specific antigen velocity in screening for prostate cancerKazuto Ito
Department of Urology, Gunma University School of Medicine, Maebashi, Japan
Int J Urol 9:316-21. 2002..of prostate-specific antigen velocity (PSAV) was investigated in relation to the initial prostate-specific antigen (PSA) value in subjects with initial values of 1.0-4...
- Prostate-specific antigen spikes after permanent prostate brachytherapyGregory S Merrick
Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV 26003 6300, USA
Int J Radiat Oncol Biol Phys 54:450-6. 2002To evaluate whether any clinical, treatment, or dosimetric parameters correlated with the development of a prostate-specific antigen (PSA) spike after permanent prostate brachytherapy.
- Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-spBob Djavan
Department of Urology, University of Vienna, Austria
Urology 60:4-9. 2002..Cancer Detection study evaluated the value and performance of the molecular forms of prostate-specific antigen (PSA) and their derivatives in combination with prostate gland and transition zone volumes in early detection of ..
- Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analoguesT Bjork
Department of Urology, Malmö and Lund University Hospitals, Lund University, Malmo, Sweden
Prostate 47:14-20. 2001Our recently reported finding of rapid bi-exponential elimination of free prostate-specific antigen (PSA) after radical retropubic prostatectomy in patients with moderately elevated PSA levels, which contrasted a very slow, linear ..
- Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliterWolfgang Horninger
Department of Urology, University of Innsbruck, Austria
Urology 60:31-5. 2002Complexed PSA (cPSA) has been shown to improve specificity in the detection of prostate cancer over that of total PSA (tPSA) testing in men with tPSA values greater than the cutoff value of 4.0 ng/mL...
- Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lowerIan M Thompson
Department of Urology, University of Texas Health Science Center at San Antonio, TX 78229, USA
JAMA 294:66-70. 2005Three fourths of US men older than 50 years have been screened with prostate-specific antigen (PSA) for prostate cancer.
- Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH databaseRobert J Hamilton
Division of Urologic Surgery, Department of Surgery, Duke University School of Medicine, Durham, North Carolina 27710, USA
J Urol 179:1785-9; discussion 1789-90. 2008b>Prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy is a powerful predictor of prostate cancer specific and overall death...
- Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancerH B Carter
Department of Urology, Johns Hopkins Hospital, Baltimore, MD 21287 2101, USA
JAMA 277:1456-60. 1997To evaluate prostate-specific antigen (PSA) testing intervals that maintain the detection of curable cancer and reduce unnecessary testing.
- Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trialW J Catalona
Division of Urologic Surgery, Washington University School of Medicine, St Louis, MO 63110, USA
JAMA 279:1542-7. 1998The percentage of free prostate-specific antigen (PSA) in serum has been shown to enhance the specificity of PSA testing for prostate cancer detection, but earlier studies provided only preliminary cutoffs for clinical use.
- Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) Simon M Collin
Department of Social Medicine, University of Bristol, Bristol, UK
BJU Int 102:1400-6. 2008To determine associations of lower urinary tract symptoms (LUTS) with prostate-specific antigen (PSA) levels and screen-detected localized and advanced prostate cancer.
- Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screeningKazuto Ito
Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan
Cancer 103:242-50. 2005In the current study, the authors set out to investigate the possibility that increased prostate-specific antigen (PSA) levels in Dutch and Japanese men without suspicious findings at initial prostate cancer screening were indicative of ..
- [Clinical value of prostate specific antigen screening in early detection of prostate cancer]Li Xin Hua
Department of Urological Surgery, First Affiliated Hospital, Nanjing Medical University, Nanjing, China
Zhonghua Zhong Liu Za Zhi 31:705-9. 2009To evaluate the clinical significance of prostate-specific antigen (PSA) screening in early detection of prostate cancer in Chinese men.
- Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasiaC A Mochtar
Department of Urology, Academic Medical Centre, University of Amsterdam, G4 105 1, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Eur Urol 44:695-700. 2003To assess the ability of serum prostate specific antigen (PSA) to estimate prostate volume (PV) to aid in the management of patients with benign prostatic hyperplasia (BPH).
- Serum prostate-specific antigen concentration is increased in acromegalic womenL Manetti
Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy
J Endocrinol Invest 27:643-7. 2004Prostate-specific antigen (PSA) is a serine proteases produced by prostatic epithelial cells detectable in male serum and seminal plasma...
- Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostateP Henttu
Biocenter, University of Oulu, Finland
Int J Cancer 45:654-60. 1990Human glandular kallikrein-1 gene (hGK-1) is closely related to the gene of human prostate-specific antigen (PSA) and both genes are expressed in the human prostate...
- Clinical usefulness of free PSA in early detection of prostate cancerH J Luboldt
Klinik und Poliklinik fur Urologie, Kinderurologie und Urologische Onkologie, Universitatsklinikum Essen, Gesamthochschule Essen, Essen
Onkologie 24:33-7. 2001Measurement of serum prostate-specific antigen (PSA) is widely used as an aid in early detection of prostate cancer. Most patients with prostate cancer and a PSA level less than 10.0 ng/ml have early-stage disease...
- Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab menM Sheikh
Department of Radiology, Faculty of Medicine, Kuwait University, P O Box 24923, 13110, Safat, Kuwait
Int Urol Nephrol 37:721-6. 2005This study was undertaken to assess the utility of prostate specific antigen (PSA) and PSA density (PSAD) in discriminating between benign and malignant prostate disease in the Kuwaiti Arab population.
- Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day)Sittiporn Srinualnad
Division of Urology, Department of Surgery, Faculty of Medicine, Siriraj Hospital 10700, Thailand
J Med Assoc Thai 89:37-42. 2006..The prevalence of prostate cancer continues to rise. Serum PSA (Prostate Specific Antigen) can be used as a screening tool for detection of early prostate cancer However, a screening program for ..
- Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancerDarren M Mitchell
Department of Clinical Oncology, Christie NHS Trust, Manchester, UK
Radiother Oncol 88:102-7. 2008..To report on the incidence of benign prostate-specific antigen bounce following permanent I(125) prostate brachytherapy, to describe the associations in our population and review the relationship of bounce to subsequent biochemical failure...
- Pamela L Paris; Fiscal Year: 2015..The advent of widespread PSA (prostate specific antigen) screening has resulted in increased detection of prostate cancer and detection at earlier stages of ..
- Kathryn Radabaugh Nightingale; Fiscal Year: 2014..States and Europe to detect PCa, which include digital rectal examination (DRE), and prostate-specific antigen (PSA) analysis...
- A Serum Marker for Aggressive Prostate CancerDonna M Peehl; Fiscal Year: 2010DESCRIPTION (provided by applicant): The PSA era is over. In the U.S...
- Alicia C McDonald; Fiscal Year: 2015..DESCRIPTION (provided by applicant): Prostate cancer is one of the most common cancers in U.S. men. Serum prostate specific antigen (PSA) test, a biomarker of prostate cancer, and the digital rectal examination (DRE) have been used for ..
- Detecting Prostate Cancer using multi-protocol 3 Tesla in vivo MRI and MRSAnant Madabhushi; Fiscal Year: 2009..The current protocol to diagnose CAP in the USA is to have patients with elevated prostate specific antigen (PSA) levels undergo a trans-rectal ultrasound (TRUS)-directed biopsy...
- A bioelectronic assay for PSA activityDimitra Georganopoulou; Fiscal Year: 2010..The principal goal of this SBIR proposal is to develop an assay for prostate-specific antigen (PSA) proteolytic enzyme activity to improve the early diagnosis and prognosis of prostate cancer...
- Sebastiano Gattoni-Celli; Fiscal Year: 2016..enroll 136 Veteran subjects (68 participants per arm), diagnosed with low-risk prostate cancer (Gleason score d6, PSA d10, clinical stage T1C or T2a)...
- Glycan Biomarkers of Prostate Cancer in Prostatic FluidsRichard R Drake; Fiscal Year: 2012Prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) are glycoproteins secreted by prostate epithelial cells, and have a long clinical history of use as serum biomarkers of prostate cancers...
- DAVID MICHAEL SCHUSTER; Fiscal Year: 2016..Approximately 50% of patients who have undergone post-prostatectomy radiotherapy after Prostate Specific Antigen (PSA) failure or biopsy proven prostate bed recurrence manifest subsequent systemic disease, in part, ..
- Russell S Taichman; Fiscal Year: 2015..localized prostate cancer (PCa) when he presented for a routine physical exam and was found to have a prostate specific antigen (PSA) blood test of 5.2...
- Development of Nonhuman Primate Models for PSA Biology StudiesJAMES NKAMBWE MUBIRU; Fiscal Year: 2013..These diseases are a cause of significant mortality and morbidity. Prostate specific antigen (PSA) is released at increased levels into the blood early in the development of these diseases and ..
- Robot-Assisted MRI-Guided Prostate BiopsyDan Stoianovici; Fiscal Year: 2010..6 billion. Biopsies are typically triggered by elevated prostate specific antigen (PSA) tests, which are highly sensitive but insufficiently specific for PC...
- Prostate Cancer Detection by Molecular UrinalysisChristian P Pavlovich; Fiscal Year: 2010..S. men >55 years of age over a 7 year period. Currently used screening tests (serum prostate-specific antigen (PSA) and digital rectal exam) have shown only modest predictive value, and serum PSA isoforms have added little ..
- A Molecular targeting agent for systemic radiotherapy of metastatic Prostate CancKevin P Maresca; Fiscal Year: 2010..Blood PSA (Prostate Specific Antigen) screening and digital rectal exams can detect early warning signs of prostate cancer but an effective ..
- Small Integrin-binding Glycophosphoproteins as Biomarkers for Prostate CancerNeal S Fedarko; Fiscal Year: 2013....
- Glycoproteins and Glycan-Binding IgGs: Biomarkers for Cancer and Inflammatory DiHyesook Kim; Fiscal Year: 2013..Increased prostate-specific antigen (PSA) coreprotein levels have been widely used to detect, stage and monitor prostate cancer...
- Tatiana Khokhlova; Fiscal Year: 2016..g., Prostate Specific Antigen (PSA) tests, often fail to differentiate between the two...
- Tea Polyphenols in Chemoprevention of Prostate CancerSUSANNE MARGARETE HENNING; Fiscal Year: 2011..Serum prostate specific antigen and IGF-1/IGFBP-3 will be determined using chemiluminescent analysis...
- Robert J Klein; Fiscal Year: 2016..year, over 1,000,000 needless prostate biopsies are performed on men who present with elevated levels of prostate specific antigen (PSA) but show no evidence of cancer upon biopsy...
- Proximal Prostate Fluids for Protein and miRNA BiomarkersRichard R Drake; Fiscal Year: 2010Detection of prostate specific antigen (PSA) levels in serum as a biomarker of prostate cancer continues to evolve to reflect new knowledge about disease-specific isoforms and free versus bound complexes with serum proteins...
- [F18]FMAU in Prostate CancerHossein Jadvar; Fiscal Year: 2010..Approximately 30% of men with detectable serum prostate-specific antigen (PSA) levels after curative radical prostatectomy have local recurrences while about 40% are expected to have distant ..
- Single Molecule Fiber Arrays for the Detection of Low Abundance ProteinsDavid C Duffy; Fiscal Year: 2013..Using single molecule detection, prostate specific antigen (PSA) was detected in serum at concentrations less than 1 femtomolar;current immunoanalyzers have an LOD ..
- Gene Networks for Prostate Cancer ProgressionLeif Peterson; Fiscal Year: 2005..tissue during radical retropubic prostatectomy (RPP) and short doubling time (<10 months) for serum prostate specific antigen (PSA)...
- Genetic Susceptibility for Prostate Cancer ProgressionWilliam Isaacs; Fiscal Year: 2009..As many as 25% or more men who undergo this treatment will experience a re-elevation in their serum Prostate Specific Antigen (PSA) level within months to years later...
- James Marshall; Fiscal Year: 2015..Diet change will be evaluated by 24-hour recalls and by blood carotenoids. Disease will be monitored by PSA and appropriate clinical surveillance for 24 months...
- Prostate, Lung, Colorectal and Ovarian (PLCO) Screening TrialMona Fouad; Fiscal Year: 2013..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
- Prostate, Lung, Colorectal and Ovarian (PLCO) Screening TrialBARBARA O'BRIEN; Fiscal Year: 2013..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
- Detection of Prostate Cancer Genomic Signatures in BloodAmin I Kassis; Fiscal Year: 2010..The diagnosis of prostate cancer (PC) is usually subsequent to routine prostate-specific antigen (PSA) determination in blood and/or discovery of a palpable mass within the prostate (following rectal examination) that ..
- PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIALPaul Kvale; Fiscal Year: 2010..For prostate cancer, men received six annual prostate screens with prostate-specific antigen (PSA) and four digital rectal exams (DRE)...
- PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIALKAREN STEINMETZ; Fiscal Year: 2011
- Prostate, Lung, Colorectal and Ovarian (PLCO) Screening TrialMona Fouad; Fiscal Year: 2011
- Prostate, Lung, Colorectal and Ovarian (PLCO) Screening TrialBARBARA O'BRIEN; Fiscal Year: 2011
- Prostate, Lung, Colorectal and Ovarian (PLCO) Screening TrialSaundra Buys; Fiscal Year: 2009
- Prostate, Lung, Colorectal and Ovarian (PLCO) Screening TrialMona Fouad; Fiscal Year: 2009
- Prostate, Lung, Colorectal and Ovarian (PLCO) Screening TrialMona Fouad; Fiscal Year: 2010
- Prostate, Lung, Colorectal and Ovarian (PLCO) Screening TrialBARBARA O apos BRIEN; Fiscal Year: 2009
- PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIALClaudine Isaacs; Fiscal Year: 2009
- Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial - LabCheryl Robinson; Fiscal Year: 2009
- PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIALClaudine Isaacs; Fiscal Year: 2010
- Prostate, Lung, Colorectal and Ovarian (PLCO) Screening TrialBARBARA O apos BRIEN; Fiscal Year: 2010
- WILLIAM GEORGE NELSON; Fiscal Year: 2016..The Research Projects are supported by an Administrative Core (A), which also manages inter-SPORE collaborations, a Tissue Archive Core (B), and a Biostatistics and Epidemiology Core (C). ..
- Martin G Pomper; Fiscal Year: 2016..The ability to fulfill that goal would eliminate the prostate-specific antigen (PSA)-mediated overdetection and overtreatment of clinically insignificant disease...
- The Role of MicroRNAs in Prostate Cancer ProgressionAURORA ESQUELA KERSCHER; Fiscal Year: 2010..Prostate-specific antigen (PSA) is a widely used diagnostic marker for prostate cancer that can result in the treatment of insignificant disease ..
- Hari K Koul; Fiscal Year: 2014..Tet inhibited Prostate Specific Antigen (PSA) synthesis and secretion, blocked cell cycle progression and growth of human PCa cells in culture, ..
- Decision Making in Unaffected First-Degree Relatives of Prostate Cancer PatientsClement Gwede; Fiscal Year: 2009DESCRIPTION (provided by applicant): The use of the prostate specific antigen (PSA) test in the general population and identifiable high-risk subgroups remains controversial, and the PSA test remains the only available test to date to ..
- Identification of Colon Cancer Protein Biomarkers in the BloodWILFRIDO DIOKNO MOJICA; Fiscal Year: 2010..approaches suggest the potential to identify candidate CRC-selective biomarker proteins, akin to Prostate Specific Antigen (PSA) for prostate cancer or CA125 for ovarian cancer...
- Methylated Galectin-3 DNA as a Marker for Early Diagnosis of Prostate CancerHafiz Ahmed; Fiscal Year: 2010..Combined with the digital rectal examination, the prostate specific antigen (PSA) test has been widely used to detect prostate cancer in its early stages...
- MATHEW LAXMAN THAKUR; Fiscal Year: 2016..Serum prostate specific antigen (PSA) measurements, transrectal ultrasonography (TRUS) and magnetic resonance imaging (MRI) remain ..
- Alpha Methyl AcylCoa Racemase (AMACR)Martin G Pomper; Fiscal Year: 2010..The ability to fulfill that goal would eliminate the prostate-specific antigen (PSA)-mediated over detection and overtreatment of clinically insignificant disease...
- Decision Making For Active Surveillance in Prostate Cancer Patients and SpousesChristian J Nelson; Fiscal Year: 2013..Over the past years, widespread prostate specific antigen (PSA) screening has resulted in the earlier detection of these cancers...
- Complementary and Alternative Medicine for Urological Symptoms (CAMUS)Andrew L Avins; Fiscal Year: 2010....
- Tianying Wu; Fiscal Year: 2014..Public Health Implications: (1) Prostate-specific antigen (PSA) screening has low specificity but high sensitivity. Our goal is to complement PSA screening...
- Metabolomic Markers for Early Detection of Prostate CancerArun Sreekumar; Fiscal Year: 2010..Clinically, early detection of prostate cancer is guided by levels of prostate specific antigen (PSA)...
- Effects of Stereotype Threat on the Health-Related Outcomes of African AmericansPaul R Jones; Fiscal Year: 2011..If threat is a problem, the project will develop guidelines for designing health communication and refining cultural competency training and practice that avoid raising stereotype threat. ..
- Prostate-Specific Antigen Practices and Outcomes in the ElderlyLouise C Walter; Fiscal Year: 2013Project Summary/Abstract Prostate-specific antigen (PSA) screening for the early detection of prostate cancer has been widely adopted in the U.S. among elderly men, including those with limited life expectancy...
- Leo L Cheng; Fiscal Year: 2016DESCRIPTION (provided by applicant): Serum prostate specific antigen testing improved early detection of prostate tumors, increased diagnosed prostate cancer (PCa) incidence, and shifted newly detected PCa treatment to earlier stages...
- Andrew J Vickers; Fiscal Year: 2015..are unnecessary: the most common reason for a prostate biopsy is an elevated level of prostate-specific antigen (PSA) in the blood, but most men with elevated PSA do not have prostate cancer...
- Emanuela Taioli; Fiscal Year: 2014..g., over-diagnosis because of enhanced surveillance and screening with prostate specific antigen [PSA]) would represent an important message to WTCHP members...
- ROBIN JEAN LEACH; Fiscal Year: 2014..for control of this disease is currently early diagnosis and treatment, relying primarily on the Prostate Specific Antigen (PSA) blood test for detection. Unfortunately, for most men with a PSA above 4...
- Jennifer Dacey Allen; Fiscal Year: 2014..5 times more likely to die from the disease than White men. Screening with prostate specific antigen (PSA) is the main method of early detection, although it remains of unproven benefit...
- Daniel B Vigneron; Fiscal Year: 2016..Due to increased screening using serum prostate specific antigen (PSA) and extended-template transrectal ultrasound (TRUS) guided biopsies, patients with prostate cancer ..
- Sarah E Woolf-King; Fiscal Year: 2016..We will accomplish this aim by: (a) using a qualitative test for Prostate Specific Antigen (PSA), an indicator of recent (i.e...
- Stephen K Van Den Eeden; Fiscal Year: 2015DESCRIPTION (provided by applicant): The advent of prostate-specific antigen (PSA) testing in the late 1980s has led to a dramatic rise in prostate cancer (PCa) incidence...
- Grace Lu-Yao; Fiscal Year: 2014..follow-up and unavailability of key prognostics factors such as detailed Gleason scores and baseline prostate specific antigen (PSA) data...
- Real-time detection of cancer biomarkers using a self-sustained aptazymeCharles Olea; Fiscal Year: 2013..As proof-of-principle, two aptazymes specific for cancer biomarkers prostate-specific antigen (PSA) and p21-activated kinase (PAK1) will be developed...
- Profiling Urine Glycosylation of PSA and other Glyco-Biomarkers in Prostate CanceLewis Pannell; Fiscal Year: 2009..We observed significant levels of both prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) in the urine from healthy individuals, consistent with some ..
- ACTIVATION OF PROSTATE SPECIFIC ANTIGEN PRECURSORThomas Takayama; Fiscal Year: 2000b>Prostate specific antigen (PSA) is a prostatic enzyme with biological significance. As a proteolytic enzyme, it cleaves seminal coagulum proteins to release sperm for fertilization...
- Early detection of prostate cancer in urineHafiz Ahmed; Fiscal Year: 2010..Combined with the digital rectal examination, the prostate specific antigen (PSA) test has been widely used to detect prostate cancer in its early stages...
- FORMS OF PROSTATE SPECIFIC ANTIGEN AND HK2 IN CANCERMARY HEEB; Fiscal Year: 2003We seek to extend promising studies showing that prostate specific antigen (PSA) and glandular kallikrein (hK2) occur in several forms in blood of prostate cancer (CaP) patients and that measurement of the proportion of PSA in the form ..
- The functions of affect in treatment decicions of rising PSA patientsMichael A Diefenbach; Fiscal Year: 2010DESCRIPTION (provided by applicant): The widespread use of prostate-specific antigen (PSA) testing has enabled physicians to closely monitor patients who have been treated for prostate cancer...
- Anti-GM1b IgM for Detection of Localized Prostate CancerMepur Ravindranath; Fiscal Year: 2005..Prostate-specific antigen (PSA) is widely used for diagnosing and monitoring CaP...
- Development of an anti-PSA IgE to treat prostate cancerBirgit Schultes; Fiscal Year: 2009DESCRIPTION (provided by applicant): The present proposal seeks to develop a novel anti-prostate specific antigen (PSA) IgE antibody for the treatment of prostate cancer (PCA) with the goal to induce a hypersensitivity reaction to the ..
- Human cDNAs and proteins and uses thereofPatent Number: WO03046180-A2; Date:2003-06-05